Holen Sie sich die Stockscreener-App
2.92
81.04%
-12.48
Handel nachbörslich:
2.92
Schlusskurs vom Vortag:
$15.40
Offen:
$15.6
24-Stunden-Volumen:
3.15M
Relative Volume:
8.27
Marktkapitalisierung:
$222.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-88.94%
1M Leistung:
-90.49%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.81
$15.90
1-Wochen-Bereich:
$2.81
$28.10
52-Wochen-Spanne:
$2.81
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MENS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.92 | 1.17B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week LowHere's Why - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3%Here's What Happened - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownWhat's Next? - MarketBeat
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2025. - marketscreener.com
Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq
Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat
Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World
Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World
Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat
Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com
Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets
Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Shares Gap UpWhat's Next? - MarketBeat
Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga
Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat
Jyong Biotech Stock (MENS) Opinions on Phase II Trial Results - Quiver Quantitative
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com
Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech Announces Completion of Primary Endpoint - GlobeNewswire
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech is Now Oversold (MENS) - Nasdaq
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com Australia
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Es liegen keine Finanzdaten für Jyong Biotech Ltd (MENS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):